within Pharmacolibrary.Drugs.ATC.N;

model N05AA02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.36,
    Cl             = 0.028333333333333332,
    adminDuration  = 600,
    adminMass      = 0.05,
    adminCount     = 1,
    Vd             = 0.0148,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005333333333333333,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Levomepromazine is a typical antipsychotic of the phenothiazine group, used primarily in the treatment of schizophrenia and psychosis, and also for severe agitation or restlessness. It exhibits antihistaminic, anticholinergic, and antiadrenergic properties as well. It is still approved and used in several countries, but not widely used in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult psychiatric patients after oral administration.</p><h4>References</h4><ol><li><p>Hals, PA, &amp; Dahl, SG (1982). Pharmacokinetics and first-pass metabolism of levomepromazine in the rat. <i>Acta pharmacologica et toxicologica</i> 50(2) 148–154. DOI:<a href=&quot;https://doi.org/10.1111/j.1600-0773.1982.tb00956.x&quot;>10.1111/j.1600-0773.1982.tb00956.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7072505/&quot;>https://pubmed.ncbi.nlm.nih.gov/7072505</a></p></li><li><p>Dahl, SG, et al., &amp; Sigfusson, S (1977). Pharmacokinetics and relative bioavailability of levomepromazine after repeated administration of tablets and syrup. <i>European journal of clinical pharmacology</i> 11(4) 305–310. DOI:<a href=&quot;https://doi.org/10.1007/BF00607681&quot;>10.1007/BF00607681</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/862652/&quot;>https://pubmed.ncbi.nlm.nih.gov/862652</a></p></li><li><p>Bagli, M, et al., &amp; Möller, HJ (1995). Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects. <i>International journal of clinical pharmacology and therapeutics</i> 33(12) 646–652. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8963481/&quot;>https://pubmed.ncbi.nlm.nih.gov/8963481</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05AA02;
